Adaptimmune Therapeutics, a biopharmaceutical company developing cancer immunotherapy treatments, is planning to expand its presence in Philadelphia at a new 46,000-square-foot facility at the Philadelphia Navy Yard – a project that will create 110 new jobs over the next three years.
The company — which is based in Oxford, England, and has offices in the Center City — plans to invest more than $4 million at the site that will be developed by Liberty Property Trust and Synterra. The total project cost is expected to exceed $25 million.
AdaptImmune (NASDAQ: ADAP) is receiving state support for the project, including a $150,000 grant from the Pennsylvania Department of Community and Economic Development’s Pennsylvania First Program. The project was coordinated by the Governor’s Action Team and the Philadelphia Industrial Development Corp.
Read the full story here.
For more business news, visit PBJ.com.
